Zimmer Biomet Holdings Inc (ZBH) Shares Bought by State of Wisconsin Investment Board

State of Wisconsin Investment Board increased its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.3% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 255,624 shares of the medical equipment provider’s stock after buying an additional 669 shares during the quarter. State of Wisconsin Investment Board’s holdings in Zimmer Biomet were worth $30,846,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of Nova Scotia Trust Co. bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at about $112,000. FNY Managed Accounts LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at about $117,000. Cerebellum GP LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $133,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at about $140,000. Finally, Chesley Taft & Associates LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $202,000. Institutional investors own 88.18% of the company’s stock.

Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $120.48 on Monday. The stock has a market capitalization of $24,393.96, a P/E ratio of 13.37, a P/E/G ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet Holdings Inc has a 52 week low of $108.03 and a 52 week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the previous year, the company posted $2.14 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. research analysts predict that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a $0.24 dividend. The ex-dividend date was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio is presently 10.65%.

In related news, VP Chad F. Phipps sold 20,826 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.07% of the stock is currently owned by insiders.

A number of research firms have issued reports on ZBH. Jefferies Group restated a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks boosted their price target on Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research note on Monday, January 29th. Stifel Nicolaus restated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $141.67.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings Inc (ZBH) Shares Bought by State of Wisconsin Investment Board” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/02/19/zimmer-biomet-holdings-inc-zbh-shares-bought-by-state-of-wisconsin-investment-board.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply